The board of directors of the Critical Path Institute (C-Path), an independent, nonprofit organization, have named Martha Brumfield, Ph.D., as interim president and CEO. Brumfield, C-Path’s former director of international and regulatory programs, will take over immediately for Carolyn Compton, M.D., Ph.D. who will be assuming a new position at Arizona State University (ASU).

Compton, a professor at ASU, will now devote her full-time efforts to the National Biomarkers Development Alliance, a biomarker initiative that is based at ASU. Compton, who has a lifelong passion for cancer research with a focus on biomarkers and biospecimans, helped plan the initiative along with the founding partners, ASU, C-Path and the International Genomic Consortium. Additionally, she is the chair of the American Joint Committee on Cancer and an executive committee member of the Commission on Cancer of the American College of Surgeons. Prior to C-Path, Compton held leadership positions at the National Cancer Institute, the College of American Pathologists, and was a professor of Pathology at Harvard Medical School.